We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
Turnover
32.84%
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
+14.09%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$328M
AUM Growth
-$33M
(-9.1%)
Cap. Flow
-$50.7M
Cap. Flow
% of AUM
-15.44%
Top 10 Holdings %
Top 10 Hldgs %
48.5%
Holding
63
New
10
Increased
14
Reduced
12
Closed
20
Avg Time Held
1.2
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lexicon Pharmaceuticals
LXRX
|
+$8.86M |
| 2 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$8.46M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
+$5.89M |
| 4 |
VRML
Vermillion, Inc.
VRML
|
+$4.93M |
| 5 |
Arvinas
ARVN
|
+$4.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$11.2M |
| 2 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
+$10.4M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
+$10.3M |
| 4 |
Catalyst Pharmaceutical
CPRX
|
+$9.31M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$7.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.92% |
| 2 | Miscellaneous | 1.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Ironwood Pharmaceuticals
IRWD
$623M
| $5.75M | 1.75% |
+525,400
| New | +$5.89M |
2019 Q2
0 quarters
|
|
27
Acadia Pharmaceuticals
ACAD
$3.4B
| $5.35M | 1.63% |
200,000
| – | – |
2018 Q3
3 quarters
|
|
|
28
Arvinas
ARVN
$468M
| $4.84M | 1.47% |
+220,000
| New | +$4.62M |
2019 Q2
0 quarters
|
|
|
VRML
29
DELISTED
Vermillion, Inc.
VRML
| $3.78M | 1.15% |
+4,250,000
| New | +$4.93M |
2019 Q2
0 quarters
|
|
30
Zymeworks
ZYME
$1.85B
| $3.74M | 1.14% |
170,000
+115,000
| +209% | +$2.11M |
2018 Q4
2 quarters
|
|
|
SBBP
31
DELISTED
Strongbridge Biopharma plc.
SBBP
| $3.57M | 1.09% |
1,140,000
-12,500
| -1% | -$45.9K |
2016 Q4
10 quarters
|
|
32
Viking Therapeutics
VKTX
$3.48B
| $3.32M | 1.01% |
400,000
-85,000
| -18% | -$726K |
2017 Q4
6 quarters
|
|
|
AIMT
33
DELISTED
Aimmune Therapeutics
AIMT
| $2.71M | 0.83% |
130,000
-35,000
| -21% | -$721K |
2018 Q4
2 quarters
|
|
34
Aquestive Therapeutics
AQST
$510M
| $2.48M | 0.76% |
+590,000
| New | +$3.02M |
2019 Q2
0 quarters
|
|
35
DELISTED
Synthorx, Inc. Common Stock
THOR
| $2.13M | 0.65% |
157,600
+117,600
| +294% | +$1.89M |
2019 Q1
1 quarter
|
|
|
RARX
36
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $1.53M | 0.47% |
+51,000
| New | +$1.17M |
2019 Q2
0 quarters
|
|
37
Fennec Pharmaceuticals
FENC
$363M
| $1.18M | 0.36% |
295,000
-335,000
| -53% | -$1.42M |
2017 Q4
6 quarters
|
|
|
ARQL
38
DELISTED
Arqule Inc
ARQL
| $1.1M | 0.34% |
+100,000
| New | +$696K |
2019 Q2
0 quarters
|
|
39
DELISTED
Crinetics Pharmaceuticals
CRNX
| $900K | 0.27% |
36,000
-37,000
| -51% | -$916K |
2019 Q1
1 quarter
|
|
40
Protalix BioTherapeutics
PLX
$218M
| $469K | 0.14% |
+100,000
| New | +$423K |
2019 Q2
0 quarters
|
|
41
GridAI Technologies Corp
GRDX
$31.8M
| $247K | 0.08% |
+1
| New | +$286K |
2019 Q2
0 quarters
|
|
42
BioLineRX
BLRX
$10.2M
| $91K | 0.03% |
417
| – | – |
2013 Q4
22 quarters
|
|
43
Abeona Therapeutics
ABEO
$266M
| – | – |
-22,400
| Closed | -$4.12M | – |
|
44
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-115,000
| Closed | -$2.24M | – |
|
|
45
Ascendis Pharma A/S
ASND
$14.9B
| – | – |
-95,000
| Closed | -$11.2M | – |
|
46
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-50,000
| Closed | -$2.65M | – |
|
|
47
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-1,825,000
| Closed | -$9.31M | – |
|
48
Establishment Labs
ESTA
$1.83B
| – | – |
-50,000
| Closed | -$1.2M | – |
|
49
Kura Oncology
KURA
$863M
| – | – |
-25,200
| Closed | -$418K | – |
|
50
Liquidia Corp
LQDA
$3.11B
| – | – |
-225,000
| Closed | -$2.56M | – |
|
Similar funds
CFO
PFM
HBCM
AI
TPA
ZDA
NW
TFA
Opaleye Management's Q2 2019 Portfolio in Review
As of Q2 2019, Opaleye Management held 63 positions worth $328M, down 9.1% from $361M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Opaleye Management withdrew a net $50.7M in Q2 2019, closing 20 positions and reducing 12 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $11.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, Opaleye Management opened a new position in Lexicon Pharmaceuticals worth $9.31M.
- Opaleye Management's largest Q2 2019 buy was Lexicon Pharmaceuticals: 1,480,000 shares worth $9.31M.
- Opaleye Management added most to Ocular Therapeutix in Q2 2019, an estimated $3.89M increase.
- Opaleye Management's biggest Q2 2019 reduction was Axogen, cutting an estimated $4.28M.
- Opaleye Management fully exited Ascendis Pharma A/S in Q2 2019, selling an estimated $11.2M.
- Opaleye Management's ten largest holdings make up 49% of its $328M portfolio in Q2 2019.
- Opaleye Management opened 10 new positions and closed 20 in Q2 2019.
- Opaleye Management's portfolio value fell 9.1% quarter-over-quarter to $328M.
Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.